Literature DB >> 25941604

Tumor-associated antigen specific CD8+ T cells in hepatocellular carcinoma - a promising target for immunotherapy.

Nathalie Schmidt1, Tobias Flecken2, Robert Thimme1.   

Abstract

Immunotherapy is a promising treatment option for patients with hepatocellular carcinoma (HCC). Indeed, CD8+ T-cell responses against various tumor antigens occur in these patients. However, these antitumoral T cells show a severely impaired effector function. Several immunosuppressive mechanisms contribute to this T-cell failure, including regulatory T cells and inhibitory receptors.

Entities:  

Keywords:  AFP, α-fetoprotein; CD8+ T cells; HCC, hepatocellular carcinoma; HLA, human leukocyte antigen; IFNγ, interferon-γ; IL, interleukin; MAGE-A1, melanoma-associated gene-A1; NY-ESO-1, New York-esophageal squamous cell carcinoma-1; PD-1; PD-1, programmed death-1; PD-L1, PD-ligand-1; T-cell failure; TAA, tumor-associated antigen; Treg, regulatory T cells; hepatocellular carcinoma; immunotherapy; melanoma; regulatory T cells; tumor-associated antigens

Year:  2014        PMID： 25941604      PMCID： PMC4292268          DOI： 10.4161/21624011.2014.954919

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.

Authors:  T Takayama; T Sekine; M Makuuchi; S Yamasaki; T Kosuge; J Yamamoto; K Shimada; M Sakamoto; S Hirohashi; Y Ohashi; T Kakizoe
Journal:  Lancet       Date:  2000-09-02       Impact factor: 79.321

Review 2.  Hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  N Engl J Med       Date:  2011-09-22       Impact factor: 91.245

Review 3.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

4.  A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.

Authors:  Lisa H Butterfield; Antoni Ribas; Vivian B Dissette; Yohan Lee; Jin Quan Yang; Pilar De la Rocha; Sonia D Duran; Jackie Hernandez; Elisabeth Seja; Douglas M Potter; William H McBride; Richard Finn; John A Glaspy; James S Economou
Journal:  Clin Cancer Res       Date:  2006-05-01       Impact factor: 12.531

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

7.  Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma.

Authors:  Robert Thimme; Michaela Neagu; Tobias Boettler; Christoph Neumann-Haefelin; Nadine Kersting; Michael Geissler; Frank Makowiec; Robert Obermaier; Ulrich T Hopt; Hubert E Blum; Hans Christian Spangenberg
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

8.  Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.

Authors:  Tobias Flecken; Nathalie Schmidt; Sandra Hild; Emma Gostick; Oliver Drognitz; Robert Zeiser; Peter Schemmer; Helge Bruns; Thomas Eiermann; David A Price; Hubert E Blum; Christoph Neumann-Haefelin; Robert Thimme
Journal:  Hepatology       Date:  2014-02-20       Impact factor: 17.425

9.  A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

Authors:  Daniel H Palmer; Rachel S Midgley; Noweeda Mirza; Elizabeth E Torr; Forhad Ahmed; Jane C Steele; Neil M Steven; David J Kerr; Lawrence S Young; David H Adams
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425
  9 in total
  9 in total

Review 1.  High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy.

Authors:  Suresh Gopi Kalathil; Yasmin Thanavala
Journal:  Cancer Immunol Immunother       Date:  2016-02-24       Impact factor: 6.968

Review 2.  Trial Watch-Oncolytic viruses and cancer therapy.

Authors:  Jonathan Pol; Aitziber Buqué; Fernando Aranda; Norma Bloy; Isabelle Cremer; Alexander Eggermont; Philippe Erbs; Jitka Fucikova; Jérôme Galon; Jean-Marc Limacher; Xavier Preville; Catherine Sautès-Fridman; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

3.  Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC.

Authors:  Akira Asai; Yusuke Tsuchimoto; Hideko Ohama; Shinya Fukunishi; Yasuhiro Tsuda; Makiko Kobayashi; Kazuhide Higuchi; Fujio Suzuki
Journal:  Oncoimmunology       Date:  2017-03-03       Impact factor: 8.110

4.  An immune-inflamed tumor microenvironment as defined by CD8 score is associated with favorable oncologic outcomes in hepatocellular carcinoma independent of measures of tumor mutational burden.

Authors:  Leonid Cherkassky; Masanori Oshi; Eihab Abdelfatah; Rongrong Wu; Yamato Takabe; Li Yan; Itaru Endo; Kazuaki Takabe
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

5.  Hepatoma cell-derived leptin downregulates the immunosuppressive function of regulatory T-cells to enhance the anti-tumor activity of CD8+ T-cells.

Authors:  Renxiong Wei; Yaoren Hu; Feibo Dong; Xiaozhen Xu; Airong Hu; Guosheng Gao
Journal:  Immunol Cell Biol       Date:  2015-12-07       Impact factor: 5.126

6.  Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.

Authors:  Valerie Chew; Liyun Lai; Lu Pan; Chun Jye Lim; Juntao Li; Raymond Ong; Camillus Chua; Jing Yao Leong; Kiat Hon Lim; Han Chong Toh; Ser Yee Lee; Chung Yip Chan; Brian K P Goh; Alexander Chung; Pierce K H Chow; Salvatore Albani
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-03       Impact factor: 11.205

7.  TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors.

Authors:  Timothy T Spear; Glenda G Callender; Jeffrey J Roszkowski; Kelly M Moxley; Patricia E Simms; Kendra C Foley; David C Murray; Gina M Scurti; Mingli Li; Justin T Thomas; Alexander Langerman; Elizabeth Garrett-Mayer; Yi Zhang; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-02-03       Impact factor: 6.968

Review 8.  Recent advances in systemic therapy for hepatocellular carcinoma.

Authors:  Huajun Zhang; Wuyang Zhang; Longying Jiang; Yongheng Chen
Journal:  Biomark Res       Date:  2022-01-09

Review 9.  Immune-based therapies for hepatocellular carcinoma.

Authors:  David J Pinato; Nadia Guerra; Petros Fessas; Ravindhi Murphy; Takashi Mineo; Francesco A Mauri; Sujit K Mukherjee; Mark Thursz; Ching Ngar Wong; Rohini Sharma; Lorenza Rimassa
Journal:  Oncogene       Date:  2020-03-10       Impact factor: 9.867
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.